Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDRAE VANDROSS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1205079373
CMS profile
2789901
Location
AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,083.01

10 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $935.64 5
Food and Beverage $147.37 5

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $935.64 5
Tempus AI, Inc $49.84 2
Deciphera Pharmaceuticals Inc. $41.25 1
JAZZ PHARMACEUTICALS INC. $33.77 1
Novartis Pharmaceuticals Corporation $22.51 1

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDRAE VANDROSS

NPI 1205079373 · CMS profile ID 2789901

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1205079373?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDRAE VANDROSS, NPI 1205079373, CMS profile ID 2789901. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205079373?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ANDRAE VANDROSS, NPI 1205079373, CMS profile ID 2789901. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205079373?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ANDRAE VANDROSS, NPI 1205079373, CMS profile ID 2789901, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1205079373?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

10 matching records · $1,083.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 10 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–10 of 10.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $57.1312/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106269842 CMS
JAZZ PHARMACEUTICALS INC. $33.7712/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150204062 CMS
ABBVIE INC. $523.4308/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106269838 CMS
ABBVIE INC. $82.2008/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106269840 CMS
ABBVIE INC. $183.6608/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106269834 CMS
ABBVIE INC. $89.2208/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106269836 CMS
Tempus AI, Inc $28.7306/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150176366 CMS
Deciphera Pharmaceuticals Inc. $41.2506/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145875799 CMS
Novartis Pharmaceuticals Corporation $22.5105/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087436420 CMS
Tempus AI, Inc $21.1103/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150176364 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $175.94 3
PY2020 $44.69 3
PY2021 $107.19 6
PY2022 $430.20 11
PY2023 $385.16 4
PY2024 $1,083.01 10
PY2025 $3,168.19 7

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $874,433.33 238
PY2024 Principal investigator $413,921.09 482
PY2023 Principal investigator $420,700.05 715
PY2022 Principal investigator $499,990.99 172
PY2021 Principal investigator $187,276.47 47

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

172 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2022 Non-covered Recipient Entity
NEXT ONCOLOGY AUSTIN
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 889829127
Principal investigator 1 Exelixis Inc. $3,065.85 12/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765829
Principal investigator 1 Exelixis Inc. $1,040.85 12/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765831
Principal investigator 1 Exelixis Inc. $270.00 12/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765833
Principal investigator 1 Exelixis Inc. $3,871.80 12/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765835
Principal investigator 1 Exelixis Inc. $4,105.35 12/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765837
Principal investigator 1 Exelixis Inc. $1,175.85 12/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765839
Principal investigator 1 Exelixis Inc. $1,175.85 12/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765841
Principal investigator 1 Exelixis Inc. $1,310.85 12/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765843
Principal investigator 1 Exelixis Inc. $1,175.85 12/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765845
Principal investigator 1 Exelixis Inc. $275.00 12/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765847
Principal investigator 1 Exelixis Inc. $500.00 12/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765849
Principal investigator 1 Exelixis Inc. $275.00 12/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765851
Principal investigator 1 Exelixis Inc. $500.00 12/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765853
Principal investigator 1 Exelixis Inc. $250.00 12/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765855
Principal investigator 1 Exelixis Inc. $235.00 12/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765857
Principal investigator 1 Exelixis Inc. $350.00 12/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765859
Principal investigator 1 Exelixis Inc. $315.00 12/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765861
Principal investigator 1 Exelixis Inc. $50.00 12/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765863
Principal investigator 1 Exelixis Inc. $1,292.90 12/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765865
Principal investigator 1 ABBVIE INC. $1,601.10 12/05/2022 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 889823003
Principal investigator 1 ABBVIE INC. $5,134.05 12/05/2022 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 889823007
Principal investigator 1 ABBVIE INC. $1,601.10 12/05/2022 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 889823009
Principal investigator 1 ABBVIE INC. $2,214.00 12/05/2022 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 889823011
Principal investigator 1 ABBVIE INC. $4,313.25 12/05/2022 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 889823013
Principal investigator 1 ABBVIE INC. $4,735.80 12/05/2022 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 889823015
Principal investigator 1 ABBVIE INC. $3,523.50 12/05/2022 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 889823019
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $300.00 11/29/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO, LLC
A PHASE 1, OPEN LABEL DOSE-ESCALATION AND COHORT EXPANSION STUDY OF LUNA18 MONOTHERAPY IN AND COMBINATION THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 950701799
Principal investigator 1 Deciphera Pharmaceuticals Inc. $608.00 11/23/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953500401
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,715.00 11/23/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953500409
Principal investigator 1 Deciphera Pharmaceuticals Inc. $455.00 11/23/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953500415
Principal investigator 1 Deciphera Pharmaceuticals Inc. $473.00 11/23/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953500421
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,561.00 11/21/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953500333
Principal investigator 1 Deciphera Pharmaceuticals Inc. $926.10 11/21/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953500339
Principal investigator 1 Deciphera Pharmaceuticals Inc. $410.40 11/21/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953500345
Principal investigator 1 Deciphera Pharmaceuticals Inc. $59.00 11/21/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953500351
Principal investigator 1 Deciphera Pharmaceuticals Inc. $463.05 11/17/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953500315
Principal investigator 1 Exelixis Inc. $3,315.60 11/11/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765567
Principal investigator 1 Exelixis Inc. $1,175.85 11/11/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765569
Principal investigator 1 Exelixis Inc. $3,740.85 11/11/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765571
Principal investigator 1 Exelixis Inc. $2,173.50 11/11/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765573
Principal investigator 1 Exelixis Inc. $688.50 11/11/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765575
Principal investigator 1 Exelixis Inc. $1,243.35 11/11/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765577
Principal investigator 1 ABBVIE INC. $4,313.25 11/10/2022 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 889820535
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,700.00 11/04/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO, LLC
A PHASE 1, OPEN LABEL DOSE-ESCALATION AND COHORT EXPANSION STUDY OF LUNA18 MONOTHERAPY IN AND COMBINATION THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 950701793
Principal investigator 1 Exelixis Inc. $1,175.85 10/31/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765299
Principal investigator 1 Exelixis Inc. $3,740.85 10/31/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765301
Principal investigator 1 Exelixis Inc. $1,040.85 10/31/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765303
Principal investigator 1 Exelixis Inc. $270.00 10/31/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765305
Principal investigator 1 Exelixis Inc. $270.00 10/31/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765307
Principal investigator 1 Exelixis Inc. $2,173.50 10/31/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943765309
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 10/26/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953498951
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,034.00 10/26/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953498957
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,870.00 10/26/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953498963
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,143.00 10/26/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953498967
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 10/26/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953498973
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,768.00 10/26/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953498979
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 10/26/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953498985
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 10/26/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953498991
Principal investigator 1 Deciphera Pharmaceuticals Inc. $473.00 10/26/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953498995
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,438.00 10/26/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953499001
Principal investigator 1 ABBVIE INC. $75.00 10/20/2022 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 889816933
Principal investigator 1 ABBVIE INC. $75.00 10/20/2022 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 889816941
Principal investigator 1 Merck Sharp & Dohme LLC $42,600.00 10/20/2022 Non-covered Recipient Entity
NEXT AUSTIN
A Phase 1,1b Dose Escalation,Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 940392593
Principal investigator 1 Deciphera Pharmaceuticals Inc. $12,852.00 10/19/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953498693
Principal investigator 1 Deciphera Pharmaceuticals Inc. $18,880.00 10/19/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953498705
Principal investigator 1 Deciphera Pharmaceuticals Inc. $14,483.19 10/19/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC DBA NEXT ONCOLOGY
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953498711
Principal investigator 1 Exelixis Inc. $4,105.35 09/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943762989
Principal investigator 1 Exelixis Inc. $1,175.85 09/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943762991
Principal investigator 1 Exelixis Inc. $3,862.35 09/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943763003
Principal investigator 1 Exelixis Inc. $1,175.85 09/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943763005
Principal investigator 1 Exelixis Inc. $1,290.60 09/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943763007
Principal investigator 1 Exelixis Inc. $450.00 09/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943763011
Principal investigator 1 Exelixis Inc. $500.00 09/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943763013
Principal investigator 1 Exelixis Inc. $365.00 09/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943763015
Principal investigator 1 Exelixis Inc. $350.00 09/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943763017
Principal investigator 1 Exelixis Inc. $315.00 09/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943763019
Principal investigator 1 Exelixis Inc. $3,871.80 09/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943763037
Principal investigator 1 Exelixis Inc. $1,175.85 09/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943763069
Principal investigator 1 Exelixis Inc. $1,175.85 09/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943763071
Principal investigator 1 Exelixis Inc. $1,310.85 09/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943763073
Principal investigator 1 Exelixis Inc. $4,361.85 09/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943763259
Principal investigator 1 Exelixis Inc. $270.00 09/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943763261
Principal investigator 1 Exelixis Inc. $1,175.85 09/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943763263
Principal investigator 1 Exelixis Inc. $500.00 09/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943763265
Principal investigator 1 Exelixis Inc. $275.00 09/19/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943763267
Principal investigator 1 Deciphera Pharmaceuticals Inc. $750.00 09/14/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953497253
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,820.00 09/14/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953497259
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,000.00 09/14/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953497263
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,725.00 09/14/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953497269
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $4,384.80 09/13/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF AUSTIN - NEXT ONCOLOGY
A PHASE 1 OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF LUNA18 MONOTHERAPY IN AND COMBINATION THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 950727803
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,792.00 08/26/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953495269
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,438.00 08/26/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953495273
Principal investigator 1 Exelixis Inc. $1,175.85 08/15/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943762951
Principal investigator 1 Exelixis Inc. $1,290.60 08/15/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943762953
Principal investigator 1 Exelixis Inc. $4,361.85 08/15/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943762955
Principal investigator 1 Exelixis Inc. $1,310.85 08/15/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943763057
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $4,811.40 08/05/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF AUSTIN - NEXT ONCOLOGY
A PHASE 1 OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF LUNA18 MONOTHERAPY IN AND COMBINATION THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 950727807
Principal investigator 1 Deciphera Pharmaceuticals Inc. $473.00 07/28/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953493847
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,438.00 07/28/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953493853
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 07/28/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953493859
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,034.00 07/28/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953493865
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,870.00 07/28/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953493869
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,143.00 07/28/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953493875
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,506.00 07/28/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953493881
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 07/28/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953493887
Principal investigator 1 Deciphera Pharmaceuticals Inc. $297.00 07/28/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953493891
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,438.00 07/28/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953493897
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491833
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,034.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491839
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,870.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491845
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,143.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491851
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491857
Principal investigator 1 Deciphera Pharmaceuticals Inc. $473.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491863
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,438.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491869
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,768.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491875
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491881
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,034.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491887
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,870.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491893
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,143.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491897
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491903
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,768.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491909
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,506.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491915
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491921
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,438.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491927
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,506.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491933
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491939
Principal investigator 1 Deciphera Pharmaceuticals Inc. $473.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491945
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,034.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491949
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,870.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491955
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,143.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491961
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,438.00 07/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953491965
Principal investigator 1 Exelixis Inc. $235.00 06/13/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943760937
Principal investigator 1 Exelixis Inc. $450.00 06/13/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943760939
Principal investigator 1 Exelixis Inc. $1,250.00 06/13/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943760941
Principal investigator 1 Exelixis Inc. $450.00 06/13/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943760943
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,438.00 06/08/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953489105
Principal investigator 1 Deciphera Pharmaceuticals Inc. $12,650.00 06/01/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953488909
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,541.00 05/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953487719
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,541.00 05/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953487723
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,418.00 05/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953487729
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,418.00 05/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953487733
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,800.00 05/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953487739
Principal investigator 1 Deciphera Pharmaceuticals Inc. $550.00 05/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953487745
Principal investigator 1 Deciphera Pharmaceuticals Inc. $550.00 05/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953487751
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,995.00 05/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953487757
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,000.00 05/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953487761
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,000.00 05/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953487767
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,000.00 05/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953487773
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 05/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953487779
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 05/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953487785
Principal investigator 1 Deciphera Pharmaceuticals Inc. $928.00 05/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953487791
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,438.00 05/25/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations No dispute reported 06/30/2026 953487797
Principal investigator 1 Exelixis Inc. $450.00 05/16/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943760931
Principal investigator 1 Exelixis Inc. $500.00 05/16/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943760933
Principal investigator 1 Exelixis Inc. $365.00 05/16/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943760935
Principal investigator 1 Exelixis Inc. $1,544.40 05/16/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943760947
Principal investigator 1 Exelixis Inc. $3,871.80 05/16/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943760949
Principal investigator 1 ABBVIE INC. $1,315.00 04/21/2022 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 889787815
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $4,567.50 04/21/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO, LLC
A PHASE 1 OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF LUNA18 MONOTHERAPY IN AND COMBINATION THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 950743945
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,995.00 04/18/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO, LLC
A PHASE 1 OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF LUNA18 MONOTHERAPY IN AND COMBINATION THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 950743951
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,300.00 04/18/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO, LLC
A PHASE 1 OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF LUNA18 MONOTHERAPY IN AND COMBINATION THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 950743957
Principal investigator 1 Exelixis Inc. $3,871.80 04/11/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943760945
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $685.00 03/31/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO, LLC
A PHASE 1 OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF LUNA18 MONOTHERAPY IN AND COMBINATION THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 950757395
Principal investigator 1 ABBVIE INC. $24,750.00 03/21/2022 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 889782177
Principal investigator 1 Exelixis Inc. $750.00 03/14/2022 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio, LLC. DBA NEXT Oncology- XB002-101; Site#2104
A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 943761823
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $22,319.55 02/03/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO, LLC
A PHASE 1 OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF LUNA18 MONOTHERAPY IN AND COMBINATION THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 950757401
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,589.00 02/03/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO, LLC
A PHASE 1 OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF LUNA18 MONOTHERAPY IN AND COMBINATION THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 950757419
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $685.00 01/14/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO, LLC
A PHASE 1 OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF LUNA18 MONOTHERAPY IN AND COMBINATION THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 950757407
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,324.00 01/14/2022 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO, LLC
A PHASE 1 OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF LUNA18 MONOTHERAPY IN AND COMBINATION THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 950757413
Principal investigator 1 AstraZeneca UK Limited $9,901.00 01/13/2022 Non-covered Recipient Entity
NEXT ONCOLOGY
An Open label Non randomised Multicentre Study to Allow Continued Access to and Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours Enrolled in Adavosertib Clinical Pharmacology Studies No dispute reported 06/30/2026 914603831
Principal investigator 1 AstraZeneca UK Limited $37,351.90 01/10/2022 Non-covered Recipient Entity
NEXT ONCOLOGY
A Phase I Open-label Non-randomised Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) Rifampicin (a CYP3A4 Inducer) and Omeprazole (a Proton Pump Inhibitor) on the Pharmacokinetics of a Single Oral Dose of Adavosertib in Patients with Advanced Solid Tumours No dispute reported 06/30/2026 914604687